Hassen Sayeed

• Global Fellow, Federal Circuit Bar Association (2016-2017)
• New York Super Lawyers, IP Litigation Rising Star (2014-2015)

Bar Admissions

• New York

Court Admissions

• US District Court, Eastern and Southern Districts of New York
• US Court of Appeals, Federal Circuit
• US Supreme Court

• Harvard Law School, J.D.
• Brown University Medical School, M.D.
• Harvard College, A.B.

Member

• American Intellectual Property Law Association
• American Medical Association
• Federal Circuit Bar Association
• Intellectual Property Owners Association (Pharmaceutical and Biotechnology Issues Committee; Women in IP Committee; Presidential Task Force on Diversity, Inclusion, and Leadership)
• New York Intellectual Property Association (Patent Litigation Committee)
• New Jersey Intellectual Property Association
• South Asian Bar Association of North America
• National Asian Pacific American Bar Association
• Muslim Bar Association of New York

Moderator

• “An In-House Perspective on Biologics/Biosimilars Litigation,” The New York Intellectual Property Law Association (February 2019)

Publications

• Co-author, “Intellectual Property Developments in Biochip Nanotechnology, 3 Nanotech Law & Bus. 1 (2006)
• Co-author, “New Developments: Financial Conflicts of Interest in Human Subjects Research,” 2 Med. Res. L. & Pol’y Rep. (BNA) 421 (June 4, 2003)
• Author, “Recent Developments in Health Law, Patient Confidentiality: Hospital’s Release of Alcohol Treatment Data Does Not Violate Regs,” 30 J.L. Med. & Ethics 133, 319 (2002)
• Author, “Recent Developments in Health Law, FMLA: Department of Labor Overstepped Authority,” 30 J.L. Med. & Ethics 356, 462 (2002)
• Mentioned, “Original-Patent Rule Dooms Drug Injection Complaint,” Law360 (November 17, 2014)
• Mentioned, “Appeals court won’t stop Medac from selling injectable drug,” Reuters Legal (November 17, 2014)

Speaker

• “What Can Medical Biotechnology Learn from Patent Litigation in Industrial and Agricultural Biotech?” Bio IP Counsels Committee Conference (November 14-16, 2018)
• “Life Sciences Overview 2017”, Practising Law Institute, 11th Annual Patent Law Institute, New York (April 7, 2017)
• “Ethical Considerations in Paragraph IV Practice,” American Conference Institute, Paragraph IV Disputes Conference, New York (April 25, 2016)
• “Ethical Considerations In Paragraph IV Practice: A Roadmap For 2016,” American Conference Institute, Paragraph IV Conference (April 26, 2016)
• “Inter Partes Reviews and U.S. Biopharma Litigation Strategy,” C5’s 8th Forum on Pharma & Biotech Patent Litigation 2016 (March 15, 2016)
• “Introduction To ANDA Litigation And Hot Topics For 2016,” Japan External Trade Organization Health Care Study Group (March 17, 2016)
• “Ariosa v. Sequenom: The End Of Precision Medicine?”, New York Pharma Forum (March 29, 2016)
• “Hatch-Waxman Litigation: Delisted Patents And Challenges To Personal Jurisdiction,” The Knowledge Group Webinar (January 2016)
• “Evolving Biosimilars Landscape: Opportunities and Challenges,” New York Pharma Forum (May 13, 2015)
• “Hatch-Waxman Bootcamp,” Training Series (July 2015)
• “Pharmaceutical Brand Protection For Method Claims,” The Knowledge Group Webinar (August 2015)
• “Establishing Personal and General Jurisdiction in A Paragraph IV Case,” American Conference Institute, Paragraph IV Conference Master Class (September 30, 2015)
• “Post-Grant Proceedings In Patent Litigation: Perspectives From Life Sciences & High Tech,” National Asian Pacific American Bar Association Annual Convention (2015) 
• “Abbreviated New Drug Application (ANDA) with Paragraph IV Certification: Critical Insights in 2015 – Challenges To Personal Jurisdiction,” The Knowledge Group Webinar (2015)